Lidocaine Ointment USP — Class II drug recall D-0848-2026
Ongoing recall by SUN PHARMA /TARO, reported 2026-09-23, distributed nationwide. Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long
| Recall number | D-0848-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | SUN PHARMA /TARO, Hawthorne, NY, United States |
| Recall initiated | 2026-08-31 |
| Classified | 2026-09-15 |
| Reported by FDA | 2026-09-23 |
| Distributed | Nationwide (US) |
| Quantity | 65,328 |
| Reason classes | potency, specification failure |
| NDC | 51672-3008, 51672-3008-03, 51672-3008-05 |
| Lot numbers | AD48154 |
| Expiration dates | 2027-04-30 |
Product
Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5
Reason for recall
Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0848-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-29. Not affiliated with or endorsed by FDA. Not medical or legal advice.